Entero Healthcare Solutions Promotes Abhitesh Kumar to Chief Growth Officer, Announces Strategic Acquisitions

Entero Healthcare Solutions Limited , a leading player in the healthcare supply chain sector, has announced several significant corporate updates, including a key executive promotion and strategic acquisitions to bolster its market position.

Executive Promotion

The company's Board of Directors has approved the promotion of Abhitesh Kumar from President - Retail Business & New Initiatives to Chief Growth Officer. Kumar, who holds a B.Tech in Mechanical Engineering from BITS Pilani and a Post Graduate program in Business Management from IIM Calcutta, brings over a decade of experience to his new role, including nine years in the pharmaceutical industry.

Entero Healthcare stated that Kumar has been instrumental in scaling the company's retail business since its inception. This elevation is expected to further accelerate Entero's growth trajectory.

Strategic Acquisitions

In a move to expand its market presence, Entero Healthcare has announced two significant acquisitions:

Bioaide Technologies Private Limited: The company has entered into definitive agreements to acquire an 80% stake in Bioaide Technologies. The acquisition, valued between INR 31.13 Crore to INR 36 Crore, is expected to be completed by February 15, 2026. Bioaide, incorporated in 1996, specializes in the wholesale distribution of medical devices and other healthcare products.
Anand Chemiceutics Private Limited: Entero has signed a binding Memorandum of Understanding to acquire a 51% stake in Anand Chemiceutics. This acquisition, ranging between INR 210 Crore to INR 230 Crore, is subject to due diligence and execution of definitive agreements. Anand Chemiceutics, incorporated in 2022, focuses on wholesale distribution of medical devices and turnkey projects in healthcare institutions.

Financial Performance

Entero Healthcare also released its unaudited consolidated financial results:

Metric	Q2 FY2026	Q2 FY2025
Revenue from operations	15,709.48	13,006.92
Profit before tax	446.25	347.76
Profit for the period	366.00	260.33

All figures in INR million

Employee Stock Options

The company has allotted 2,030 equity shares under its Employee Stock Option Plan 2023, increasing its total paid-up equity share capital to INR 43,51,09,370.

These developments underscore Entero Healthcare's commitment to growth and expansion in the healthcare distribution sector. The strategic acquisitions are expected to strengthen the company's market position, while the executive promotion signals a focus on driving future growth initiatives.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.80%	+0.06%	-4.42%	-20.81%	-21.04%	-7.56%

Entero Healthcare Solutions Limited , a leading healthcare supply chain company, has reported robust financial results for the second quarter and half-year ended September 30, 2025, while also announcing strategic acquisitions to bolster its market position.

Financial Highlights

For Q2 FY26, Entero Healthcare reported consolidated revenue from operations of Rs. 15,709.48 crore, marking a significant increase from Rs. 13,006.92 crore in the same quarter last year. The company's profit after tax rose to Rs. 366.00 crore, up from Rs. 260.33 crore in Q2 FY25.

Key financial metrics for H1 FY26 include:

Particulars (Rs. in crore)	H1 FY26	H1 FY25	YoY Growth
Revenue from Operations	29,747.67	23,977.28	24.1%
EBITDA	1,126.36	861.32	30.8%
Profit After Tax	668.32	465.63	43.5%

The company's EBITDA margin improved to 3.8% in H1 FY26, compared to 3.0% in H1 FY25.

Strategic Acquisitions

Entero Healthcare announced two significant acquisitions:

Bioaide Technologies Private Limited: The company will acquire an 80% stake in Bioaide for Rs. 31.13-36 crore. Bioaide, incorporated in 1996, is engaged in wholesale distribution of medical devices and healthcare products.
Anand Chemiceutics Private Limited: Entero has entered into a binding MoU to acquire a 51% stake in Anand Chemiceutics for Rs. 210-230 crore. This acquisition includes the business operations of Anand Chemiceutics and Anand Healthcare Services.

These acquisitions are expected to strengthen Entero's position in the medical devices distribution sector and expand its geographical presence.

Other Key Developments

Employee Stock Options: The company allotted 2,030 equity shares at Rs. 804 per share under its Employee Stock Option Plan 2023.
Leadership Change: Mr. Abhitesh Kumar has been elevated to the position of Chief Growth Officer, reflecting the company's focus on accelerating growth.
IPO Fund Utilization: As of September 30, 2025, Entero has utilized Rs. 930.07 crore out of the Rs. 951.33 crore net proceeds from its IPO, with the remaining funds deployed in fixed deposits and current accounts.

Prabhat Agrawal, Promoter, Managing Director and CEO of Entero Healthcare Solutions, commented, "The quarter reflects continuation of strong growth trajectory and margin expansion. We achieved an EBITDA Margin of 4% in the quarter through focus on gross margin expansion along with improvement in net working capital days."

Entero Healthcare Solutions continues to demonstrate strong financial performance while strategically expanding its market presence through acquisitions in the healthcare distribution sector.